Investing profits from the war on obesity (SeekingAlpha) - Aug 1, 2012 - Arena shares have surged from $2 to trade at $9.50 in recent months; Vivus shares have soared from $12 to trade at $22 after the news of FDA approval; Orexigen shares have moved from $3 to around $5.5 per share; Eli Lilly shares are trading at $44 with a 4.42% dividend yield
Stock price • Diabetes
|
|
...
Recently, Vivus (VVUS) received FDA approval for its obesity drug Qsymia, which was previously known as Qnexa. Vivus shares have soared from $12 to trade at $22. While its own treatment is still a ways off from going before the FDA, Orexigen Therapeutics Inc. (OREX) is also seeking to bring a weight-loss drug to market at some point in the coming years. Orexigen shares have moved from $3 to around $5.5 per share. In classic fashion, small biotechnology shares move fast based on drug news.
...
Eli Lilly (LLY) and partner Boehringer Ingelheim of Germany released results from two mid-stage studies of their new short-acting insulin, known as LY2605541. In separate studies comparing it to Lantus, it was slightly better at reducing blood sugar levels in Type 1 diabetics and about the same in Type 2 diabetics. In the eight-week Type 1 study, patients getting LY2605541 lost about 2.5 pounds on average while those on Lantus gained 1.5 pounds. Weight changes were similar, but smaller, in the Type 2 study. Eli Lilly shares are trading at $44 with a 4.42% dividend yield.
...
Both JNJ and LLY are listed as bullish with high dividend yields. NVO and SNY are listed as having neutral outlooks. The smaller biotechs (ARNA, VVUS, OREC, and AMRN) are buys on a pullback as long-term trades.
|